Merck says its Zepatier showed better efficacy and safety compared with competition in Phase III trials
US pharma giant Merck (NYSE: MRK) on Thursday said late-stage trials for its Zepatier (elbasvir and grazoprevir) to treat chronic hepatitis C (HCV), in patients who have already received therapy, showed efficacy and safety compared with the competition.
Jan Sperl, lead study investigator said: “Overall in this study, the elbasvir and grazoprevir regimen showed superior SVR rates and improvement on pre-specified safety endpoints compared to the sofosbuvir plus peginterferon and ribavirin regimen in these genotype 1- or 4-infected patients. Sofosbuvir in combination with peginterferon and ribavirin continues to be a prescribed treatment regimen in many regions, and this comparative study versus combination treatment with elbasvir and grazoprevir provides interesting and important insights.”
The drug was tested against Gilead’s (Nasdaq: GILD) Sovaldi (sofosbuvir) plus peginterferon and ribavirin, the company said in a statement.
Jan Gerstoft, clinic for infectious diseases and rheumatology, Copenhagen, Denmark, said: “Treatment regimens containing peginterferon and ribavirin are associated with certain serious side effects. This study provides evidence for the clinical potential of elbasvir and grazoprevir in chronic HCV genotype 1- or 4-infection as compared with a regimen containing peginterferon and ribavirin along with sofosbuvir.”
Zepatier was approved by the US Food and Drug Administration (FDA) in January.
Gilead Sciences has announced the acquisition of all outstanding shares of XinThera, a privately-owned biotech …
The charity Breast Cancer Now has launched a petition calling on Gilead to provide free-of-charge …